44 related articles for article (PubMed ID: 21544084)
1. Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study.
Shim YS; Pae CU; Kim SW; Kim HW; Kim JC; Koh JS
Int J Impot Res; 2011; 23(3):109-14. PubMed ID: 21544084
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments.
Melchiode Z; Nguyen T; Dawood O; Bobo GA; Hellstrom WJG
Expert Opin Investig Drugs; 2023; 32(7):635-642. PubMed ID: 37507822
[TBL] [Abstract][Full Text] [Related]
3. Testing the cognitive effects of tadalafil. Neuropsychological secondary outcomes from the PASTIS trial.
Pauls MM; Fish J; Binnie LR; Benjamin P; Betteridge S; Clarke B; Dhillon MK; Ghatala R; Hainsworth FA; Howe FA; Khan U; Kruuse C; Madigan JB; Moynihan B; Patel B; Pereira AC; Rostrup E; Shtaya AB; Spilling CA; Trippier S; Williams R; Young R; Barrick TR; Isaacs JD; Hainsworth AH
Cereb Circ Cogn Behav; 2023; 5():100187. PubMed ID: 37811523
[TBL] [Abstract][Full Text] [Related]
4. PDE5 inhibitor drugs for use in dementia.
Hainsworth AH; Arancio O; Elahi FM; Isaacs JD; Cheng F
Alzheimers Dement (N Y); 2023; 9(3):e12412. PubMed ID: 37766832
[TBL] [Abstract][Full Text] [Related]
5. Drug Discovery and Development Targeting Dementia.
Zagórska A; Czopek A; Fryc M; Jaromin A; Boyd BJ
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259302
[TBL] [Abstract][Full Text] [Related]
6. Sildenafil Alleviates Murine Experimental Autoimmune Encephalomyelitis by Triggering Autophagy in the Spinal Cord.
Duarte-Silva E; Meiry da Rocha Araújo S; Oliveira WH; Lós DB; Bonfanti AP; Peron G; de Lima Thomaz L; Verinaud L; Peixoto CA
Front Immunol; 2021; 12():671511. PubMed ID: 34054847
[TBL] [Abstract][Full Text] [Related]
7. Sulfur-containing therapeutics in the treatment of Alzheimer's disease.
Zhu H; Dronamraju V; Xie W; More SS
Med Chem Res; 2021 Feb; 30(2):305-352. PubMed ID: 33613018
[TBL] [Abstract][Full Text] [Related]
8. Memory Enhancers for Alzheimer's Dementia: Focus on cGMP.
Fedele E; Ricciarelli R
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33451088
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist.
Ribaudo G; Ongaro A; Zagotto G; Memo M; Gianoncelli A
ACS Chem Neurosci; 2020 Jun; 11(12):1726-1739. PubMed ID: 32401481
[TBL] [Abstract][Full Text] [Related]
10. Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
Hackett G
World J Mens Health; 2020 Jul; 38(3):271-284. PubMed ID: 32378365
[TBL] [Abstract][Full Text] [Related]
11. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.
Baillie GS; Tejeda GS; Kelly MP
Nat Rev Drug Discov; 2019 Oct; 18(10):770-796. PubMed ID: 31388135
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory.
Palmeri A; Ricciarelli R; Gulisano W; Rivera D; Rebosio C; Calcagno E; Tropea MR; Conti S; Das U; Roy S; Pronzato MA; Arancio O; Fedele E; Puzzo D
J Neurosci; 2017 Jul; 37(29):6926-6937. PubMed ID: 28626017
[TBL] [Abstract][Full Text] [Related]
14. PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease.
Teich AF; Sakurai M; Patel M; Holman C; Saeed F; Fiorito J; Arancio O
J Alzheimers Dis; 2016; 52(1):295-302. PubMed ID: 26967220
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition.
Peixoto CA; Nunes AK; Garcia-Osta A
Mediators Inflamm; 2015; 2015():940207. PubMed ID: 26770022
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans.
Theunissen EL; Heckman P; de Sousa Fernandes Perna EB; Kuypers KP; Sambeth A; Blokland A; Prickaerts J; Toennes SW; Ramaekers JG
Psychopharmacology (Berl); 2015 Jan; 232(2):343-53. PubMed ID: 24998257
[TBL] [Abstract][Full Text] [Related]
17. Erectile dysfunction, vascular risk, and cognitive performance in late middle age.
Moore CS; Grant MD; Zink TA; Panizzon MS; Franz CE; Logue MW; Hauger RL; Kremen WS; Lyons MJ
Psychol Aging; 2014 Mar; 29(1):163-72. PubMed ID: 24660805
[TBL] [Abstract][Full Text] [Related]
18. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.
Shim YS; Pae CU; Cho KJ; Kim SW; Kim JC; Koh JS
Int J Impot Res; 2014; 26(2):76-80. PubMed ID: 24285284
[TBL] [Abstract][Full Text] [Related]
19. Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease.
Saavedra A; Giralt A; Arumí H; Alberch J; Pérez-Navarro E
PLoS One; 2013; 8(9):e73664. PubMed ID: 24040016
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterases as therapeutic targets for Alzheimer's disease.
García-Osta A; Cuadrado-Tejedor M; García-Barroso C; Oyarzábal J; Franco R
ACS Chem Neurosci; 2012 Nov; 3(11):832-44. PubMed ID: 23173065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
